Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines (ONC) reported insider activity by its Chief Executive Officer and Director. The reporting person made two bona fide gifts of ordinary shares: 151,320 shares on 11/11/2025 and 858,533 shares on 11/12/2025, for a combined 1,009,853 shares, each at a stated price of $0 per footnote (gift). After these transactions, direct beneficial ownership stood at 6,441,041 ordinary shares.
The filing also lists indirect holdings, including 481,533 (P&O Trust), 7,722,480 (a grantor retained annuity trust), 28,204,115 (Oyler Investment LLC), 9,545,000 (Roth IRA), and 102,188 (The John Oyler Legacy Trust), as described in the footnotes with certain beneficial ownership disclaimers. No derivative securities were reported.
ONC: A shareholder filed a Form 144 notice to sell up to 6,009 shares of common stock, with an aggregate market value of $2,286,659.45. The filer lists Morgan Stanley Smith Barney LLC as broker, an approximate sale date of November 13, 2025, and the NASDAQ as the exchange.
The notice shows shares were acquired via restricted stock vesting under a registered plan on multiple dates. The table also reports 109,663,273 shares outstanding. Recent activity by the same seller over the past three months includes sales of 49,858 shares on August 13, 2025 for $15,162,320.35, 39,936 shares on August 14, 2025 for $12,180,813.46, and 10,000 shares on November 12, 2025 for $3,560,160.50.
ONC — Notice of proposed insider sale under Rule 144. A selling security holder filed a Form 144 to sell 10,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value $3,560,161.00. The shares are listed on NASDAQ, with an approximate sale date of 11/12/2025.
The filing lists prior acquisitions as restricted stock vesting under a registered plan across multiple dates, including 06/17/2023 (1,456 shares), 06/22/2023 (2,118), 06/05/2023 (4,291), 03/14/2024 (59), 09/15/2023 (52), 06/16/2023 (870), and 06/15/2024 (1,154). As context, shares outstanding were 109,663,273; this is a baseline figure, not the amount being offered.
The notice also reports sales in the past three months by Xiaobin Wu: 39,936 shares on 08/14/2025 for $12,180,813.46 and 49,858 shares on 08/13/2025 for $15,162,320.35.
BeOne Medicines (ONC): A director and Chair of the Scientific Advisory Board reported a bona fide gift of 424,073 ordinary shares on 11/07/2025 (Code G) at $0 pursuant to Rule 16b-5. Following the transaction, the director beneficially owned 4,582,601 shares directly.
Additional indirect holdings were reported with a disclaimer of beneficial ownership: 1,025,063 shares via a family trust, 3,953,100 shares via Wang Investment LLC, and 50 shares held by the spouse.
BeOne Medicines Ltd. (ONC) reported a profitable Q3. Total revenues were $1,412,284 for the three months ended September 30, 2025, driven by product revenue of $1,395,013. Net income was $124,841, a clear turnaround from a loss a year ago, as gross profit rose to $1,215,774 and operating income reached $163,114.
Cash generation was strong with year‑to‑date operating cash flow of $710,233, lifting cash and cash equivalents to $4,036,868. The company monetized future IMDELLTRA royalties, receiving $885,000 upfront from Royalty Pharma, recorded as a royalty sale liability with a 6.4% effective annual rate. BRUKINSA led product sales at $1,040,691 in the quarter, followed by TEVIMBRA at $190,623. Short‑term debt stood at $813,296 and long‑term debt at $139,571. Shares outstanding were 1,438,553,263 as of November 1, 2025.
BeOne Medicines Ltd. (ONC) filed an 8-K announcing its third-quarter 2025 results. The company reported that it announced financial results for the three months ended September 30, 2025, and furnished a related press release as Exhibit 99.1 titled “BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates.”
The information provided under Item 2.02 is being furnished and is not deemed “filed” under the Exchange Act. The filing also lists the company’s securities, including American Depositary Shares trading on Nasdaq under ONC, with each ADS representing 13 ordinary shares; the ordinary shares are listed on the Stock Exchange of Hong Kong under 06160.
John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares on 09/16/2025 under a Rule 10b5-1 trading plan adopted on March 12, 2025. The Form 4 lists six sale transactions totaling 28,203 ADS at weighted-average prices ranging approximately from $323.61 to $327.78 (footnotes provide per-transaction ranges). Each ADS represents 13 ordinary shares. The filing shows multiple pools of ordinary shares held directly or indirectly through trusts and entities, with the reporting person disclaiming beneficial ownership of certain holdings. The form is signed by an attorney-in-fact on behalf of the reporting person.
BeOne Medicines Ltd. (ONC) director Wang Xiaodong reported a change in beneficial ownership on a Form 4 covering transactions dated 09/09/2025. The filing shows 148,096 ordinary shares were disposed of under transaction code G, reported at a price of $0, and described in the footnotes as bona fide gifts exempt from Section 16(b). After the reported transaction, the Form 4 lists 5,006,674 ordinary shares as directly beneficially owned and additional indirect holdings of 1,025,063, 3,953,100, and 50 shares held through family and trust entities, with the reporting person disclaiming beneficial ownership for certain trust-held positions. The form was signed by an attorney-in-fact on 09/11/2025.
BeOne Medicines insider sale and holdings summary. The reporting person, Global Head of R&D, disclosed a sale of 5,000 American Depositary Shares (ADS) executed under a Rule 10b5-1 trading plan at a weighted average price of $350.0623 per ADS. The report shows 1,023,529 ordinary shares previously reported as disposed and an indirect beneficial ownership position of 601,965 ordinary shares held through Wang Holdings LLC. The filer also disclosed a contribution of RMB10 million to an employee participation plan that purchased RMB-denominated shares in the issuer's STAR Market offering; the filer disclaims voting and dispositive power over those RMB Shares.
BeOne Medicines Ltd. (ONC) Form 144 notice reports a proposed sale of 9,010 ADS (American Depositary Shares) through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $3,163,681.30 and approximately 54,564,278 ADS outstanding. The filing shows the securities were mainly acquired via an exercise of stock options on 09/10/2025 (8,894 ADS, paid in cash) and restricted stock units on 06/15/2025 (116 ADS). The filer disclosed prior sales in the past three months: 9,342 ADS (10b5-1 sale) on 08/13/2025 for $2,805,905.17, 920 ADS on 07/30/2025 for $280,232.74, and 422 ADS on 06/16/2025 for $112,463.00. The notice includes the usual representation about absence of undisclosed material adverse information and reference to Rule 10b5-1 trading plans where applicable.